TY - JOUR
T1 - Whole-blood RNA profiles associated with pulmonary arterial hypertension and clinical outcome
AU - Rhodes, Christopher J.
AU - Otero-Núñez, Pablo
AU - Wharton, John
AU - Swietlik, Emilia M.
AU - Kariotis, Sokratis
AU - Harbaum, Lars
AU - Dunning, Mark J.
AU - Elinoff, Jason M.
AU - Errington, Niamh
AU - Thompson, A. A.Roger
AU - Iremonger, James
AU - Coghlan, J. Gerry
AU - Corris, Paul A.
AU - Howard, Luke S.
AU - Kiely, David G.
AU - Church, Colin
AU - Pepke-Zaba, Joanna
AU - Toshner, Mark
AU - Wort, Stephen J.
AU - Desai, Ankit A.
AU - Humbert, Marc
AU - Nichols, William C.
AU - Southgate, Laura
AU - Trégouët, David Alexandre
AU - Trembath, Richard C.
AU - Prokopenko, Inga
AU - Gräf, Stefan
AU - Morrell, Nicholas W.
AU - Wang, Dennis
AU - Lawrie, Allan
AU - Wilkins, Martin R.
N1 - Funding Information:
Supported in part by the Assistance Publique-Hopitaux de Paris, INSERM, University Paris-Sud, and Agence Nationale de la Recherche (Departement Hospitalo-Universitaire Thorax Innovation; LabEx LERMIT, ANR-10-LABX-0033; and RHU BIO-ART LUNG 2020, ANR-15-RHUS-0002) and British Heart Foundation Centre for Research Excellence award RE/18/4/34215. C.J.R. is supported by a BHF Intermediate Basic Science Research fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\1095). L.H. is a recipient of ERS Fellowship (LTRF 2016–6884). A.A.R.T. is supported by a BHF Intermediate Clinical Fellowship (FS/18/13/3328). L.S. is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St. George’s, University of London. D.W. is supported by an Academy of Medical Sciences Springboard fellowship (SBF004\1052). N.W.M. is a British Heart Foundation Professor and NIHR Senior Investigator. A.L. is supported by a BHF Senior Basic Science Research fellowship (FS/13/48/30453 and FS/18/52/33808). The authors also acknowledge funding from NHLBI, R01HL136603 (A.A.D.). The UK National Cohort of Idiopathic and Heritable PAH is supported by the National Institute of Health Research BioResource, the BHF (SP/12/12/29836), and the UK Medical Research Council (MR/K020919/1). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.
Funding Information:
Supported in part by the Assistance Publique-Hopitaux de Paris, INSERM, University Paris-Sud, and Agence Nationale de la Recherche (Departement Hospitalo-Universitaire Thorax Innovation; LabEx LERMIT, ANR-10-LABX-0033; and RHU BIO-ART LUNG 2020, ANR-15-RHUS-0002) and British Heart Foundation Centre for Research Excellence award RE/18/4/34215. C.J.R. is supported by a BHF Intermediate Basic Science Research fellowship (FS/15/59/31839) and Academy of Medical Sciences Springboard fellowship (SBF004\1095). L.H. is a recipient of ERS Fellowship (LTRF 2016-6884). A.A.R.T. is supported by a BHF Intermediate Clinical Fellowship (FS/18/13/3328). L.S. is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St. George's, University of London. D.W. is supported by an Academy of Medical Sciences Springboard fellowship (SBF004\1052). N.W.M. is a British Heart Foundation Professor and NIHR Senior Investigator. A.L. is supported by a BHF Senior Basic Science Research fellowship (FS/13/48/30453 and FS/18/52/33808). The authors also acknowledge funding from NHLBI, R01HL136603 (A.A.D.). The UK National Cohort of Idiopathic and Heritable PAH is supported by the National Institute of Health Research BioResource, the BHF (SP/12/12/29836), and the UK Medical Research Council (MR/K020919/1). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.
Publisher Copyright:
Copyright © 2020 by the American Thoracic Society.
PY - 2020/8/15
Y1 - 2020/8/15
N2 - Rationale: Idiopathic and heritable pulmonary arterial hypertension (PAH) are rare but comprise a genetically heterogeneous patient group.RNA sequencing linked to the underlying genetic architecture can be used to better understand the underlying pathology by identifying key signaling pathways and stratify patients more robustly according to clinical risk. Objectives: To use a three-stage design of RNA discovery, RNA validation and model construction, and model validation to define a set of PAH-associated RNAs and a single summarizing RNA model score. To define genes most likely to be involved in disease development, we performed Mendelian randomization (MR) analysis. Methods: RNA sequencing was performed on whole-blood samples from 359 patients with idiopathic, heritable, and drug-induced PAH and 72 age- and sex-matched healthy volunteers. The score was evaluated against disease severity markers including survival analysis using all-cause mortality from diagnosis. MR used known expression quantitative trait loci and summary statistics from a PAH genome-wide association study. Measurements and Main Results: We identified 507 genes with differential RNA expression in patients with PAH compared with control subjects. A model of 25 RNAs distinguished PAH with 87% accuracy (area under the curve 95% confidence interval: 0.791-0.945) in model validation. The RNA model score was associated with disease severity and long-term survival (P = 4.66 × 10-6) in PAH. MR detected an association between SMAD5 levels and PAH disease susceptibility (odds ratio, 0.317; 95% confidence interval, 0.129-0.776; P = 0.012). Conclusions: A whole-blood RNA signature of PAH, which includes RNAs relevant to disease pathogenesis, associates with disease severity and identifies patients with poor clinical outcomes. Genetic variants associated with lower SMAD5 expression may increase susceptibility to PAH.
AB - Rationale: Idiopathic and heritable pulmonary arterial hypertension (PAH) are rare but comprise a genetically heterogeneous patient group.RNA sequencing linked to the underlying genetic architecture can be used to better understand the underlying pathology by identifying key signaling pathways and stratify patients more robustly according to clinical risk. Objectives: To use a three-stage design of RNA discovery, RNA validation and model construction, and model validation to define a set of PAH-associated RNAs and a single summarizing RNA model score. To define genes most likely to be involved in disease development, we performed Mendelian randomization (MR) analysis. Methods: RNA sequencing was performed on whole-blood samples from 359 patients with idiopathic, heritable, and drug-induced PAH and 72 age- and sex-matched healthy volunteers. The score was evaluated against disease severity markers including survival analysis using all-cause mortality from diagnosis. MR used known expression quantitative trait loci and summary statistics from a PAH genome-wide association study. Measurements and Main Results: We identified 507 genes with differential RNA expression in patients with PAH compared with control subjects. A model of 25 RNAs distinguished PAH with 87% accuracy (area under the curve 95% confidence interval: 0.791-0.945) in model validation. The RNA model score was associated with disease severity and long-term survival (P = 4.66 × 10-6) in PAH. MR detected an association between SMAD5 levels and PAH disease susceptibility (odds ratio, 0.317; 95% confidence interval, 0.129-0.776; P = 0.012). Conclusions: A whole-blood RNA signature of PAH, which includes RNAs relevant to disease pathogenesis, associates with disease severity and identifies patients with poor clinical outcomes. Genetic variants associated with lower SMAD5 expression may increase susceptibility to PAH.
KW - Pulmonary arterial hypertension
KW - RNAseq
KW - Wholeblood RNA
UR - http://www.scopus.com/inward/record.url?scp=85089611894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089611894&partnerID=8YFLogxK
U2 - 10.1164/rccm.202003-0510OC
DO - 10.1164/rccm.202003-0510OC
M3 - Article
C2 - 32352834
AN - SCOPUS:85089611894
SN - 1073-449X
VL - 202
SP - 586
EP - 594
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
IS - 4
ER -